Related Experiment Videos
Update on chronic hepatitis C in hemophiliacs
Massimo Franchini1, Franco Capra, Annarita Tagliaferri
1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, via Delle Menegone 1, 37134 Verona, Italy. giorgio.gandini@mail.azosp.vr.it
Haematologica
|May 16, 2002
Summary
Hepatitis C virus (HCV) infection significantly impacts patients with hereditary bleeding disorders. This review covers HCV prevalence, risk factors, and recent treatment advancements in hemophilia patients.
Area of Science:
- Hepatology
- Virology
- Hematology
Background:
- Hepatitis C virus (HCV) infection is a major health concern for individuals with hereditary bleeding disorders.
- Historical use of non-virus inactivated clotting factor concentrates in the 1970s led to widespread HCV transmission in this population.
Purpose of the Study:
- To review current knowledge on HCV infection in hemophilic patients.
- To analyze the natural course of HCV infection, including prevalence, genotype distribution, and progression to severe liver disease.
Main Methods:
- Systematic review of existing literature on HCV infection in hemophiliacs.
- Analysis of epidemiological data, risk factors, and clinical outcomes.
- Focus on therapeutic advancements for hepatitis C in this specific patient group.
Main Results:
- HCV infection is highly prevalent in hemophilia populations treated before viral inactivation of clotting factors.
- Key risk factors for progression to advanced liver disease (cirrhosis, HCC) are identified.
- Significant progress has been made in treating hepatitis C in hemophilic patients.
Conclusions:
- Understanding HCV natural history in hemophiliacs is crucial for managing liver disease.
- Recent therapeutic breakthroughs offer new hope for effective HCV treatment and cure in this vulnerable group.